$1.00
-0.13 (-11.50%)
Open$1.15
Previous Close$1.13
Day High$1.22
Day Low$1.00
52W High$2.93
52W Low$0.55
Volume—
Avg Volume8.05M
Market Cap222.02M
P/E Ratio—
EPS$-0.19
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,422.0% upside
Current
$1.00
$1.00
Target
$15.22
$15.22
$10.64
$15.22 avg
$24.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.86M | 2.44M | 180.17M |
| Net Income | -57,325,331 | -43,953,653 | 5.71M |
| Profit Margin | -2,003.6% | -1,903.4% | 3.2% |
| EBITDA | -89,273,880 | -72,252,671 | 9.37M |
| Free Cash Flow | — | — | 5.00M |
| Rev Growth | +17.4% | +17.4% | +21.8% |
| Debt/Equity | 20.86 | 20.86 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |